Jorunn Brekke

Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival

Mohummad Aminur Rahman, Andrea Gras Navarro, Jorunn Brekke et al. · British Journal of Cancer · 2019 · 49 citations · Full text

Medicine, Oncology, Pharmacology +17

Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients – 30 months follow‐up

Trine‐Lise Larsen, Herish Garresori, Jorunn Brekke et al. · Journal of Thrombosis and Haemostasis · 2022 · 42 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study

Mohummad Aminur Rahman, Jorunn Brekke, Victoria Smith Arnesen et al. · Immunity Inflammation and Disease · 2020 · 27 citations · Full text

Medicine, Oncology, Pharmacology +17

Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions

Hanne Blakstad, Jorunn Brekke, Mohummad Aminur Rahman et al. · PLoS ONE · 2023 · 27 citations · Full text

Medicine, Oncology, Molecular Oncology +16

Investigating survival, quality of life and cognition in PROton versus photon therapy for <i>IDH-</i> mutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and Sweden

Liv Cathrine Heggebø, Ida M. H. Borgen, H. Rylander et al. · BMJ Open · 2023 · 15 citations · Full text

Medicine, Oncology, Radiation Oncology +17